Display options
Cite
Mahmoudvand H, Kheirandish F, Mirbadie SR, et al. The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iran J Parasitol. 2017;12(3):339-347
Mahmoudvand, H., Kheirandish, F., Mirbadie, S. R., Kayedi, M. H., Rezaei Riabi, T., Ghasemi, A. A., Bamorovat, M., & Sharifi, I. (2017). The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iranian journal of parasitology, 12(3), 339-347.
Mahmoudvand, Hossein, et al. "The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of ." Iranian journal of parasitology vol. 12,3 (2017): 339-347.
Mahmoudvand H, Kheirandish F, Mirbadie SR, Kayedi MH, Rezaei Riabi T, Ghasemi AA, Bamorovat M, Sharifi I. The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of . Iran J Parasitol. 2017 Jul-Sep;12(3):339-347. PMID: 28979343; PMCID: PMC5623913.
Copy Download .nbib Format: NLM
Share it on

Iran J Parasitol. 2017 Jul-Sep;12(3):339-347.

The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of .

Iranian journal of parasitology

Hossein Mahmoudvand, Farnaz Kheirandish, Seyed Reza Mirbadie, Mohammad Hassan Kayedi, Tahereh Rezaei Riabi, Abbas Ali Ghasemi, Mehdi Bamorovat, Iraj Sharifi

Affiliations

  1. Razi Herbal Medicines Research Center, Dept. of Medical Parasitology and Mycology, Lorestan University of Medical Sciences, Khorramabad, Iran.
  2. Dept. of Medical Parasitology and Mycology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
  3. Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.

PMID: 28979343 PMCID: PMC5623913

Abstract

BACKGROUND: The present study aimed to evaluate the effect of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA, Glucantime) against sensitive and MA-resistant

METHODS: The present study was carried out in 2014 in Leishmaniasis Research Center at School of Medicine, Kerman University of Medical sciences, Kerman, Iran. The effects of MTX alone and along with MA on promastigote and amastigote stages of sensitive (SS) and MA-resistant (RS)

RESULTS: The findings of OD and IC

CONCLUSION: This study indicated high potency and a synergistic effect of MTX on MA in inhibiting the growth rateof promastigote and amastigote stages of sensitive and meglumine antimoniate-resistant

Keywords: In vitro; Leishmania tropica; Meglumine antimoniate; Methotrexate; Resistance

Conflict of interest statement

Conflict of Interests The authors declare that there is no conflict of interest in this study.

References

  1. Parasitol Res. 2008 May;102(6):1227-34 - PubMed
  2. Jpn J Infect Dis. 2008 May;61(3):210-1 - PubMed
  3. Hum Reprod Update. 2008 Jul-Aug;14(4):309-19 - PubMed
  4. J Infect Dis. 1999 Aug;180(2):564-7 - PubMed
  5. Korean J Parasitol. 2015 Feb;53(1):21-7 - PubMed
  6. Planta Med. 2016 Mar;82(4):279-84 - PubMed
  7. Acta Trop. 2007 Jul;103(1):33-40 - PubMed
  8. Parasitol Res. 2007 Oct;101(5):1319-22 - PubMed
  9. Iran J Parasitol. 2012;7(1):45-52 - PubMed
  10. Biomed Pharmacother. 2016 Aug;82:208-15 - PubMed
  11. Parasitol Res. 2010 Jul;107(2):459-63 - PubMed
  12. J Vector Borne Dis. 2014 Dec;51(4):294-9 - PubMed
  13. Comp Immunol Microbiol Infect Dis. 2004 Sep;27(5):305-18 - PubMed
  14. Bioconjug Chem. 2002 May-Jun;13(3):518-24 - PubMed
  15. Parasitol Res. 2008 Jun;103(1):1-10 - PubMed
  16. Expert Opin Pharmacother. 2001 Mar;2(3):409-17 - PubMed
  17. Pharmacol Rev. 2005 Jun;57(2):163-72 - PubMed
  18. Clin Microbiol Rev. 2006 Jan;19(1):111-26 - PubMed
  19. East Mediterr Health J. 2015 Dec 13;21(10 ):736-42 - PubMed
  20. JAMA. 1970 Oct 5;214(1):109-14 - PubMed
  21. Vaccine. 2009 Jul 30;27(35):4747-53 - PubMed
  22. Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S62-5 - PubMed
  23. PLoS Med. 2006 May;3(5):e162 - PubMed
  24. J Infect Dis. 2011 Jan 15;203(2):207-10 - PubMed
  25. Br Med J. 1972 Mar 11;1(5801):654-6 - PubMed
  26. Iran J Parasitol. 2014 Oct-Dec;9(4):452-60 - PubMed
  27. J Parasit Dis. 2016 Jun;40(2):423-6 - PubMed
  28. Arch Dermatol. 2006 Dec;142(12 ):1575-9 - PubMed
  29. Pharm Biol. 2015 Jul;53(7):1052-7 - PubMed
  30. Pharm Biol. 2016;54(5):752-8 - PubMed
  31. Evid Based Complement Alternat Med. 2015;2015:149707 - PubMed

Publication Types